Kilburn & Strode

The second article in our EPO Patentability and Clinical Trials series discusses the EPO’s approach to inventive step, and how this relates to applications based on a clinical trial. In this article, Tom Leonard and Juliette Howarth take a closer look at arguing against the EPO’s default position, reliance on a “bonus effect”, the motivation of the skilled person and important considerations for your filing strategy to ensure the claims are considered inventive. Stay tuned for the next article in the series! Read the full article by clicking the link below. #EPO #ClinicalTrials #InventiveStep

❗ Update on G1/24 ❗ We now have confirmation that the EPO Enlarged Board of Appeal will hear this case. We hope this will ultimately provide the necessary guidance on claim interpretation and whether the description and figures should be consulted when construing the meaning of patent claims. We’re closely monitoring developments in this case and will report all updates. See our article on the topic by clicking the link below. #EPO #CaseLawUpdates

One week to go, there's still time to register! https://lnkd.in/d_kKwHkT

Excitement, nerves and some friendly competition between our London and Dutch offices today as we gear up for an exciting Euros semi-final. Dat het beste team mag winnen! / May the best team win! ⚽

1 day to go. There's still time to register! It’s been just over a year since the EPO’s Enlarged Board of Appeal (EBA) handed down its landmark decision in G2/21, setting out a brand-new test for determining the admissibility of post-filed data and replacing the previously used catchword “plausibility”. So, what has been the impact of this new test? On Wednesday 10 July join our G2/21 experts Tom Leonard, Bethany Myers and Joseph Etherington, who you may remember from our “Fast Response” webinar on this topic last year, as they provide an update on how this decision has been applied (or not!) around Europe. Use the link below to find out more and secure your place: https://lnkd.in/ev_U5P4V

We're excited to host the third and final instalment of our MedTech Summer Series. 'Optimising your MedTech IP strategy in Europe: implantable medical devices and wearable tech - 18 July Join Caelia Bryn-Jacobsen, Scott Finlayson and Alexander Worley in this punchy 30-minute session as they focus in on this exciting tech field and explore what steps you can take now to optimise your IP success in Europe. You’ll hear our research on the latest filing figures and trends in this area. We will also explore steps for success, from pre-fling reviews and claim drafting for multi-platform integration, through flexible approaches to prosecution for an open-source context. We hope you can join! Use the link below to find out more and secure your place: https://lnkd.in/es8sMnTh

Thank you to everyone who attended our event as part of the Careers In Ideas Summer of IP campaign today at Kilburn & Strode in London. It was fantastic to see so much interest in careers in IP! A huge thanks to our patent panelists: Hannah Chaudry, Mehreen Sattar, Nicole Boulis, and Kevin Bartle. Special thanks to Carol Nyahasha for leading an excellent trade marks panel, and to Kilburn & Strode for hosting us. Missed the event? Visit careersinideas.org.uk for more resources (including a recording of this event to come) and other events, or alternatively, drop me a message on here. There has never been a better time to consider a career in IP.

The development of chimeric antigen receptor (CAR) technology is a classic case of a series of incremental improvements in a technical field, with each successive generation building on the previous iteration of CARs to provide a more sophisticated therapeutic approach. Nick Bassil, Jessica Duncombe, Juliette Howarth and Amy Nick take a closer look at the structures of the different chimeric antigen receptor (CAR) generations and the importance of adopting an effective patenting strategy for “improvement” type inventions to ensure that the criteria of novelty and inventive step are fully satisfied. Use the link below to read the article in full: https://lnkd.in/eAGcf7Va

Kilburn & Strode associate Ashley Cresswell is attending Barclays Eagle Labs Health Elevate 2024 today to ensure we keep on top of healthcare trends, including the future of healthcare, sustainability in healthcare and new disruptive technologies in the MedTech space. If you’d like to meet Ash at the event or you’d like to hear his key takeaways from the event, get in touch! #BarclaysHealthElevate

It’s been just over a year since the EPO’s Enlarged Board of Appeal (EBA) handed down its landmark decision in G2/21, setting out a brand-new test for determining the admissibility of post-filed data and replacing the previously used catchword “plausibility”. So, what has been the impact of this new test? On Wednesday 10 July join our G2/21 experts Tom Leonard, Bethany Myers and Joseph Etherington, who you may remember from our “Fast Response” webinar on this topic last year, as they provide an update on how this decision has been applied (or not!) around Europe. Use the link below to find out more and secure your place: https://lnkd.in/ev_U5P4V